← back to rankingTECH · Bio-Techne Corporation
Biotechnology · mkt cap $7.8B · calls: Q3 FY2026 vs Q2 FY2026
44.0 conviction · conf-adj 44
conf –
enthusiasm:24.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:0 · business_impact:4 · disruption:0 · commitment:0 · confirmation:3
Enthusiasm latest 8 / prev 5 (rising)
Bio-Techne’s AI narrative sharpened from a brief, analyst-prompted demand tailwind in Q2 to an unprompted Q3 thesis: proprietary five-decade data and internal AI protein design, plus customer AI driving high-quality biological data demand (COMET/GigaTIME example) and downstream validation spend on reagents and assays. Management never ties AI to revenue, margin, bookings, or cost savings with numbers. Credibility rests on a coherent life-science-tools linkage (data → instruments/spatial → validation reagents) and one named external AI use case, but impact remains qualitative and forward-looking.
PAST (realized)
- Q3 FY2026 | Kim Kelderman: As an example, a recently published collaboration between Providence Health and Microsoft on the GigaTIME AI framework used data sets generated on the Bio-Techne Spatial Biology platform, COMET, to convert traditional H&E pathology images into virtual 3-dimensional tissue representations.
- Q3 FY2026 | Kim Kelderman: Our models are trained on 5 decades of proprietary data, creating a meaningful competitive moat.
CURRENT (now)
- Q3 FY2026 | Kim Kelderman: we continue to see AI increasingly influence both how we operate internally and how our customers approach drug discovery.
- Q3 FY2026 | Kim Kelderman: Internally, we are leveraging AI to design novel and patentable proteins with enhanced properties, including improved heat stability, bioactivity and solubility relative to the naturally occurring proteins.
- Q3 FY2026 | Kim Kelderman: we are deploying AI throughout the organization to improve productivity and customer engagement.
- Q3 FY2026 | Kim Kelderman: AI adoption is accelerating the earliest stages of drug discovery, particularly target discovery
- Q2 FY2026 | Kim Kelderman: Overall, we do believe that AI is a great enabler not only for our customers but also for us, obviously.
FORWARD (guidance)
- Q3 FY2026 | Kim Kelderman: target discovery, which is expected to expand the number of viable programs and improve probabilities of success.
- Q3 FY2026 | Kim Kelderman: We view the growing demand for content-rich biological data sets as a durable tailwind for both our spatial biology and our proteomic analysis platforms.
- Q3 FY2026 | Kim Kelderman: Every AI-enabled insight ultimately requires biological validation, which will fuel demand for highly specific antibodies functional assays and complex recombinant proteins in mechanism of action studies, biomarker validation and preclinical workflows.
- Q2 FY2026 | Kim Kelderman: Highly likely AI will help them to be more specific in what kind of materials they want.
- Q2 FY2026 | Kim Kelderman: Highly likely because of the capabilities, the molecules, and the ingredients that they will want to use are going to be more complex.
- Q2 FY2026 | Kim Kelderman: And overall, are going to be a tailwind.
TRACK RECORD — PROMISE vs DELIVERY
—/100 (no quantified promises) no-quantified-promises 6 calls reviewed
Across six calls Bio-Techne describes generative-AI protein design and AI tailwinds qualitatively but never states a numbered AI target with a deadline. Q2 FY2025 reported six designer proteins and a vague steady launch cadence; later calls do not revisit catalog counts or AI KPIs, so promise-versus-delivery cannot be scored.
PRICED-IN (REFINED)
MEDIUMEst. revisions flat · Fwd P/E 26.0 · EV/Sales 6.5x
AI claim maps to Consumables, Instruments
Rating counts show only a mild uptick (strongBuy 1→2, holds 5→4) while consensus price targets were cut materially (lastYearAvg $64 vs lastMonth/Quarter $52.75, now flat near-term) and forward revenue is essentially flat FY25–FY26 before modest FY27 growth—so estimate revision momentum is not clearly rising. Valuation is still rich at ~26x next-FY EPS and ~6.5x EV/Sales with a very high forward PEG (~9.6), which embeds a quality/growth premium even without upward estimate migration. AI-driven efficiency or demand would most plausibly flow through Consumables (bulk of revenue) and Instruments, not the small Royalty line. Net: not “high” (no rising estimates + rich multiple combo), but not “low” either given stretched multiples on modest consensus growth—hence medium priced-in.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
4Q2 FY20252Q3 FY20256Q4 FY20252Q1 FY20262Q2 FY20268Q3 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
After sparse early mentions and an AI-protein launch, management articulated a full AI strategy linking proprietary data, COMET platforms, and reagent tailwinds in Q3 FY2026.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
6/10 qualitative impact moderate medium-term · soft evidence
Where AI matters: AI protein design and consumables tailwind from customer drug-discovery AI
Bio-Techne has real internal AI protein design and a coherent thesis linking customer AI workflows to validation reagent and spatial-data demand, but management never quantifies revenue, margin, bookings, or catalog KPIs and the GigaTIME/COMET example remains isolated.
Caveats: No quantified AI revenue, margin, or productivity impact despite rising narrative intensity; AI protein design commercial cadence unverified since early 2025 without follow-up KPIs; Customer AI tailwind assumes in-silico target expansion reliably converts to reagent pull-through, which is unproven
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 2/10
AI-generated targets still require wet-lab validation with proprietary antibodies, recombinant proteins, and spatial datasets—physical, quality-controlled inputs LLMs cannot replace—so deflation risk is limited to routine catalog SKUs rather than the core model.
OPTIONS / MARKET STRUCTURE
option liquidity: fair
proxy inputs — dollar-ADV $129M · beta 1.405 · px $49.23
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 6/10 measured.
INSIDERS selling 2 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 72 new / 76 closed positions; 270 increased / 223 reduced; institutional ownership +3.55pp; -9 net 13F holders
MGMT LANGUAGE 6/10 measured Active internal AI use; customer upside framed as positioning and tailwinds, no AI revenue metrics.
commit “Internally, we are leveraging AI to design novel and patentable proteins with enhanced properties”
commit “we are deploying AI throughout the organization to improve productivity and customer engagement”
commit “Our models are trained on 5 decades of proprietary data, creating a meaningful competitive moat”
VERBATIM AI QUOTES
“It also enhances the visibility of our solutions across digital and AI-driven platforms, making it easier for customers to identify and deploy the right tools within their workflows.”
— Kim Kelderman, Q3 FY2026
“Speaking of artificial intelligence, we continue to see AI increasingly influence both how we operate internally and how our customers approach drug discovery.”
— Kim Kelderman, Q3 FY2026
“Internally, we are leveraging AI to design novel and patentable proteins with enhanced properties, including improved heat stability, bioactivity and solubility relative to the naturally occurring proteins.”
— Kim Kelderman, Q3 FY2026
“As you are aware, AI tools are only as effective as the data that informs the model. Our models are trained on 5 decades of proprietary data, creating a meaningful competitive moat.”
— Kim Kelderman, Q3 FY2026
“And in parallel, we are deploying AI throughout the organization to improve productivity and customer engagement.”
— Kim Kelderman, Q3 FY2026
“From a customer perspective, AI adoption is accelerating the earliest stages of drug discovery, particularly target discovery, which is expected to expand the number of viable programs and improve probabilities of success.”
— Kim Kelderman, Q3 FY2026
“The effectiveness of these models depends heavily on the generation of high-quality biological data, which is an area where Bio-Techne is extremely well positioned.”
— Kim Kelderman, Q3 FY2026
“As an example, a recently published collaboration between Providence Health and Microsoft on the GigaTIME AI framework used data sets generated on the Bio-Techne Spatial Biology platform, COMET, to convert traditional H&E pathology images into virtual 3-dimensional tissue representations.”
— Kim Kelderman, Q3 FY2026
“We view the growing demand for content-rich biological data sets as a durable tailwind for both our spatial biology and our proteomic analysis platforms.”
— Kim Kelderman, Q3 FY2026
“AI also acts as a downstream demand driver for RUO reagent and assay portfolios. Every AI-enabled insight ultimately requires biological validation, which will fuel demand for highly specific antibodies functional assays and complex recombinant proteins in mechanism of action studies, biomarker validation and preclinical workflows. These applications align directly with the most differentiated and highest value sections of our portfolio.”
— Kim Kelderman, Q3 FY2026
“Overall, we do believe that AI is a great enabler not only for our customers but also for us, obviously.”
— Kim Kelderman, Q2 FY2026
“Our customers will use AI to better understand and to better drive their programs forward.”
— Kim Kelderman, Q2 FY2026
“Highly likely AI will help them to be more specific in what kind of materials they want.”
— Kim Kelderman, Q2 FY2026
“And highly likely because of the capabilities, the molecules, and the ingredients that they will want to use are going to be more complex.”
— Kim Kelderman, Q2 FY2026
“And you know, we've worked for fifty years honing our capabilities in designing but also manufacturing. In a reproducible way these ingredients in very high-quality formats and we believe that these trends will therefore play into our cards, into the strengths that we have built as a company.”
— Kim Kelderman, Q2 FY2026
“And overall, are going to be a tailwind.”
— Kim Kelderman, Q2 FY2026
ANALYST QUESTIONS ON AI
Q (Q2 FY2026, Daniel Leonard (UBS)): Given the times we're in, I would be curious for your team's thoughts on AI's impact on demand for Bio-Techne, just given the number of times Pfizer mentioned yesterday, AI is a cost-saving and productivity enhancer in R&D.
A: Kim Kelderman: Overall, we do believe that AI is a great enabler not only for our customers but also for us, obviously. Our customers will use AI to better understand and to better drive their programs forward. Highly likely AI will help them to be more specific in what kind of materials they want. And highly likely because of the capabilities, the molecules, and the ingredients that they will want to use are going to be more complex. And you know, we've worked for fifty years honing our capabilities in designing but also manufacturing. In a reproducible way these ingredients in very high-quality formats and we believe that these trends will therefore play into our cards, into the strengths that we have built as a company. And overall, are going to be a tailwind.